Press Release Aug 17 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Doxepin Tablets in two dosages. Doxepin is indicated for treating insomnia and is expected to improve sleep duration and reduce nighttime awakenings. The tablets will be produced at Zydus's facility in Moraiya, and the approval adds to the company's extensive portfolio of drug approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 11 2023
- Press Release Aug 03 2023
- Press Release Jul 27 2023
- Press Release Jul 07 2023
- Press Release Jul 04 2023
Later from Zydus Lifesciences
- Press Release Aug 24 2023
- Press Release (Revised) Aug 24 2023
- Press Release Aug 25 2023
- Press Release Aug 31 2023
- Press Release Sep 01 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences